Olynth Ha (Xylometazoline Hydrochloride)

Xylometazoline Hydrochloride selectively stimulates alpha‑adrenergic receptors on the smooth muscle of nasal blood vessels. This causes vasoconstriction, which reduces blood flow to the nasal mucosa, decreasing edema and opening the airway for faster breathing.

The appropriate dose of Olynth Ha is determined by a qualified healthcare professional based on the patient’s age, condition and response. The prescriber will provide specific instructions on the number of sprays per nostril and the duration of treatment.

Safety data for Xylometazoline Hydrochloride in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should consult their physician before using Olynth Ha to weigh potential benefits against any unknown risks.

To order Olynth Ha, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with phenylephrine‑based sprays, Xylometazoline offers a longer duration of action and a lower incidence of systemic cardiovascular effects due to its selective alpha‑adrenergic activity. However, all nasal decongestants share a risk of rebound congestion if used beyond the recommended period.

Olynth Ha should be stored at ambient temperature below 25 °C, in its original packaging, protected from moisture and direct sunlight. Keep the bottle tightly closed when not in use to maintain product stability.

Olynth Ha is applied as a nasal spray. The prescriber will advise the number of sprays per nostril, typically one to two sprays, up to a maximum of three sprays per nostril per day, and the total duration of therapy, usually not exceeding 3‑5 days.

Serious risks include rebound nasal congestion after prolonged use, elevated blood pressure, severe nasal ulceration, and rare allergic reactions such as anaphylaxis. Patients should discontinue use and seek medical attention if they experience persistent hypertension, severe nasal irritation or systemic allergic symptoms.

Olynth Ha should be avoided in individuals with known hypersensitivity to Xylometazoline or any excipients, in children under 6 years of age unless directed by a physician, and in patients with uncontrolled hypertension, severe cardiovascular disease, or those taking monoamine oxidase inhibitors.